CAR T-cell therapy

21 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Hematology-Oncology

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

By MedXY|Jul 6, 2026

This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Hematology-Oncology

CAR T-cell therapy

Latest news

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

Global Disparities in CAR T-Cell Access: HTA Analysis Reveals Only Half of G20 Countries Recommend Reimbursement

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance

ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia